Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WS

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed to Participate at May Investor Conferences

Business Wire 8 days ago

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Business Wire 8 days ago

MindMed Reports First Quarter 2024 Financial Results and Business Updates

Business Wire 9 days ago

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

Business Wire 13 days ago

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update

Business Wire May 2, 2024

MindMed to Present at Upcoming May Medical Conferences

Business Wire April 25, 2024

MindMed to Present at Upcoming April Medical Conferences

Business Wire April 2, 2024

MindMed Announces Voluntary Delisting from Cboe Canada

Business Wire April 1, 2024

MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

Business Wire March 11, 2024

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Business Wire March 7, 2024

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Business Wire March 7, 2024

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

Business Wire March 1, 2024

MindMed Reports 2023 Financial Results and Business Updates

Business Wire February 28, 2024

MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

Business Wire February 22, 2024

MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference

Business Wire February 7, 2024

MindMed Announces Business Update and Anticipated Milestones for 2024

Business Wire January 8, 2024

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Business Wire December 14, 2023

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire November 2, 2023

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Business Wire October 26, 2023

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Business Wire October 24, 2023